Ocular Therapeutix (OCUL) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q
May 9, 2018 8:01 AM EDTCantor Fitzgerald reiterated an Overweight rating and $22.00 price target on Ocular Therapeutix (NASDAQ: OCUL) following the company's 1Q earnings report. Management reported a 1Q18 year-end cash and equivalents balance of $63 million, which analyst Elemer Piros believes provides a cash runway beyond a... More
